Browse recruiting and upcoming clinical trials for Langerhans cell histiocytosis.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIChildren (0–18 years) with pathologically confirmed Langerhans cell histiocytosis involving single-system special-site single or multifocal bone lesions and no prior LCH-specific treatment.
What is being studied AITests daily oral luvometinib for pediatric single-system special-site/multifocal bone LCH.
Who can join AIAdults aged 18–70 with newly diagnosed multisystem or single‑system multifocal Langerhans cell histiocytosis who have not had prior systemic treatment.
What is being studied AITests low-dose cytarabine combined with thalidomide as a treatment for adult LCH.
Who can join AIPeople with Langerhans cell histiocytosis (LCH) or other histiocytic disorders (for example: LCH‑ND, Erdheim‑Chester, Rosai‑Dorfman).
What is being studied AITests cobimetinib (a MEK‑blocking drug) in people with histiocytic disorders (newly diagnosed in some groups, or relapsed/refractory).
Who can join AIAdults with Langerhans-cell histiocytosis and adult control participants with diffuse cystic lung disease, emphysema, or healthy smokers.
What is being studied AIBlood biomarkers and plasma DNA for diagnosis, prognosis, and treatment response in adult LCH.